



ProPharmaceuticalsGroup

Pro Pharmaceuticals Group Pty LTD

ABN: 20 605 457 430

[www.propg.com.au](http://www.propg.com.au)

Dear Healthcare Professional,

## Shortage of OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen

Pro Pharmaceuticals Group recognises the importance of supplying essential medicines in Australia and would like to advise you the change in supply status of OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen in Australia.

The Australian registered medicine, OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324 Active ingredients: Semaglutide Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd currently in shortage due to an unexpected increase in consumer demand.

Pro Pharmaceuticals Group has arranged for the supply of an alternative product, **Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA)**. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until **30<sup>th</sup> September 2022** for the following indication(s):

*Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is not tolerated or contraindicated. - in addition to other medicinal products for the treatment of type 2 diabetes.*

**Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA)** is registered and marketed in the USA by Novo Nordisk A/S.

Pro Pharmaceuticals Group recommends that healthcare professionals refer to the Australian approved Product Information for recommended dosing for various indications.

Reporting suspected adverse events is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA)** must be reported by healthcare professionals, pharmacists, and patients to the TGA at <https://www.tga.gov.au/reporting-problems> or to Pro Pharmaceuticals Group on 1300077674 or email [regulatory@propg.com.au](mailto:regulatory@propg.com.au)

Any product complaints with **Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA)** should be reported to Pro Pharmaceuticals Group on 1300 077674 or email [regulatory@propg.com.au](mailto:regulatory@propg.com.au)

For any orders please contact Pro Pharmaceuticals Group on 1300077674 or email [orders@propg.com.au](mailto:orders@propg.com.au)

Please forward this information to relevant staff members in your organisation.

For further information, please contact Pro Pharmaceuticals Group on 1300077674 or email [info@propg.com.au](mailto:info@propg.com.au)

Sincerely,

Sandip Manku – Director Pro Pharmaceuticals Group